Antengene Entered into a Clinical Collaboration with MSD to Evaluate ATG-037 + Keytruda (pembrolizumab) for Solid Tumors
Shots:
- The companies collaborated to initiate the P-I (STAMINA-001) dose-finding study of ATG-037 (CD73 inhibitor) as monotx. & in combination with Keytruda for LA or metastatic solid tumors. The study will be conducted by Antengene & MSD providing Keytruda for the combination portions of the trial
- The primary objective is to evaluate the safety & tolerability of ATG-037 as monotx. & in combination with Keytruda along with determining the appropriate dose for P-II studies. The secondary objectives incl. the characterization of pharmacology & evaluation of preliminary efficacy
- The patient enrollment is ongoing in Australia & will include the combination with Keytruda in 2023. ATG-037 showed a promising preclinical efficacy as a monotx. and in combination with ICIs & CT agents
Ref: PRNewswire | Image: Antengene
Related News:- Antengene Receives the US FDA’s IND Clearance of ATG-017 to Initiate P-I (ERASER) Trial for Advanced Solid Tumors
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
